FibroGen, Inc.'s new CMO, Deyaa Adib, MD isn't fazed by the competition in prostate cancer. Their FG-3246 boasts an impressive 8.7 months PFS in Phase 1, and they're calling out others to show their data! Here's the challenge: PSA isn't the only measure that matters, PFS is key. They believe FG-3246 stacks up well against competitors, even Novartis' Pluvicto. Intrigued? Different companies report data differently, making comparisons tricky. Stay tuned as more info emerges, but FibroGen seems confident they're in the fight! #ProstateCancer #ClinicalTrials #ADC #FibroGen FibroGen throws down the prostate cancer gauntlet | ApexOnco - Clinical Trials news and analysis (oncologypipeline.com)
Paul Anderson’s Post
More Relevant Posts
-
Opportunity
📍 Gaithersburg, MD 🧪 Associate Scientist/Scientist (Cell Therapy) Juliana Cano-Mejia, Ph.D. is #hiring for an exciting opportunity on her AstraZeneca Cell Culture and Fermentation Sciences team! This position will involve performing experiments to design, optimize, characterize, and scale up consistent CAR-T cell processes. You will also execute cell therapy experiments and projects through cross-functional interactions with various functions within Biopharmaceutical Development. We are looking for someone that has a solid background in immunology and cell culture, as well as sound knowledge of CAR-T upstream processes. We are initially welcoming applications over the next 7 days, so click the link below to learn more & apply today! https://lnkd.in/e2KQkTTr #cellculture #immunology #cartcelltherapy #azjobs #opportunity #greatplacetowork2023
To view or add a comment, sign in
-
-
Do you want to work for a small but powerful company? If you’re ready to roll up your sleeves and work hard to sell, send us your resume. We are currently hiring for the New England area, St. Louis area, and California/Arizona area. More than a decade ago, the founders of our company took on the challenge of bringing a first-of-its-kindmedication to the pediatric oncology market. They persevered through seemingly insurmountable odds, year after year. We will continue to fight until patients are appropriately treated. Hashtags: #Oncology #OncologySales #OncologySalesProfessional #PharmaceuticalSales #PharmaceuticalSalesProfessional #Hiring #HiringSales #SalesPeople #SalesMen #SalesWomen #Pharmaceuticals #Pharma #FennecPharma #Ciaplatin #Ototoxicity #HearingLoss
To view or add a comment, sign in
-
Good Opportunity
I have multiple open positions (Director and Associate Director) to help deliver the exciting new therapies of Merck 's immunology pipeline. Are you a good fit? https://lnkd.in/d7QNRvP3
Quantitative Pharmacology & Pharmacometrics | Merck Careers
jobs.merck.com
To view or add a comment, sign in
-
🌐 Exciting Growth Potential in the Central Lab Market! 📈 Explore the dynamic landscape of the central lab market with insights from The Business Research Company's latest report. From 8.6% CAGR in 2024 to an anticipated $4.15 billion by 2028, the trajectory is promising. Key trends driving this growth include personalized healthcare, biomarker research, telemedicine, and global health challenges. 🔍 #MarketAnalysis #HealthcareTrends #BusinessInsights #CentralLabMarket #Innovation 🚀 Major Trends to Watch: 1️⃣ Technological Advancements 2️⃣ Innovative Solutions 3️⃣ Strategic Collaborations Chronic Disease Prevalence is a significant catalyst, with a focus on continuous testing and monitoring. In the US alone, an anticipated 1.9 million new cancer cases in 2022 underline the critical role of central labs. 🌐 #ChronicDiseases #HealthcareInnovation #MarketGrowth 🌐 Key Players Shaping the Industry: 🔬 Celerion Inc. 🔬 Cerba Research 🔬 Eurofins Central Laboratory LLC 🔬 Labcorp Drug Development India Private Limited 🔬 Sonic Healthcare Limited 🔬 Quest Diagnostics Explore the full report at [Link to Report]. 💡 Innovative Offerings Driving Market Dynamics: 🧪 LabVantage Analytics by LabVantage Solutions Inc. - A self-service advanced analytics platform for actionable business insights. Transforming data analysis in the central lab market! 🌐 #InnovativeSolutions #MarketDynamics #HealthcareAnalytics 🌐 Strategic Acquisitions Spotlight: In December 2021, Thermo Fisher Scientific acquired PPD Inc. for $17.4 billion, fortifying its position in clinical research services. Witness the industry's evolution through collaborations and acquisitions. 🤝 #StrategicAcquisitions #HealthcareEvolution #ThermoFisherScientific 📊 Market Segmentation: 1️⃣ Service Type Genetic Services Biomarker Services Microbiology Services Anatomic Pathology or Histology Specimen Management And Storage Special Chemistry Services Other Service Types 2️⃣ Test Type Human And Tumor Genetics Clinical Chemistry Medical Microbiology And Cytology Other Esoteric Tests 3️⃣ End-User Pharmaceutical Companies Academic And Research Institutes Biotechnology Companies 🌐 #MarketSegmentation #HealthcareIndustry 🌍 Regional Dynamics: In 2023, North America emerged as the largest region, while Asia-Pacific is projected to be the fastest-growing. The global nature of the central lab market underscores its potential impact on healthcare worldwide. 🌏 #GlobalHealthcare #MarketDynamics #CentralLab In conclusion, the central lab market is at the forefront of transforming healthcare. With a focus on innovation, strategic collaborations, and addressing the rising prevalence of chronic diseases, the market is poised for continued growth and evolution. 👉 Read more: https://lnkd.in/gSBsMVGR
Global Central Lab Market Report 2024 – Top Market Trends And Opportunities
https://healthcareresearchreports.com
To view or add a comment, sign in
-
Immuno-oncology is a rapidly developing field with the potential to revolutionize #cancertreatment. 🌟 Report deep dive - Exploring Immuno-Oncology: Challenges and Opportunities in PD1/PDL1 Inhibitor Clinical Trials 🌟 Programmed Cell Death Protein 1/Programmed Death Ligand 1 (PD1/PDL1) inhibitors are a class of drugs that have shown remarkable efficacy in combating a variety of malignancies. However, there are still challenges and opportunities in the PD1/PDL1 inhibitor #clinicaltrial landscape. Let's explore the opportunities: - Novel combination therapies: PD1/PDL1 inhibitors can be used in combination with other therapies to improve efficacy. - Predictive biomarkers: Predictive biomarkers can be used to identify patients who are most likely to benefit from PD1/PDL1 inhibitor treatment. - Expanding patient access: There are opportunities to expand patient access to clinical trials and to make PD1/PDL1 inhibitors more affordable. The report concludes by calling for a concerted effort to address the challenges and seize the opportunities in the PD1/PDL1 inhibitor clinical trial landscape. To gain a deeper understanding of the challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape, I invite you to read the full report through the following link: 🔗 Link to the IQVIA Report: "Challenges and Opportunities in the PD1/PDL1 Inhibitor Clinical Trial Landscape" https://buff.ly/46YhR0V #ImmunoOncology #PD1PDL1Inhibitors #CancerResearch #ClinicalTrials #MedicalAdvancements #PatientOutcomes #Innovation #Collaboration #MedicalWriting #RegulatoryWriting #BhamPharma #medicalcommunications #medcomms
To view or add a comment, sign in
-